ArticleThe New England journal of medicine2021
Tocilizumab in Covid-19.
Article in The New England journal of medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Mucosal implications of oral Jak3-targeted drugs in COVID patients.Molecular medicine (Cambridge, Mass.) · 2025Review
- Determination of Serum Levels of Interleukin-6 and the Trace Element Zinc According to the Clinical Status of Patients With COVID-19.Interdisciplinary perspectives on infectious diseases · 2025Article
- Development and external validation of a prediction model for the transition from mild to moderate or severe form of COVID-19.European radiology · 2023Article
- Observational
- New Advances in Viral and Microorganism Disinfectants.Microorganisms · 2023Article
- The role of SARS-COV-2 infection in promoting abnormal immune response and sepsis: A comparison between SARS-COV-2-related sepsis and sepsis from other causes.Infectious medicine · 2023Article
- Tocilizumab Is Associated with Increased Risk of Fungal Infections among Critically Ill Patients with COVID-19 and Acute Renal Failure: An Observational Cohort Study.Life (Basel, Switzerland) · 2023Article
- Therapeutic advances in COVID-19.Nature reviews. Nephrology · 2023Review
- Hyper-inflammatory responses in COVID-19 and anti-inflammatory therapeutic approaches.BMB reports · 2022Article
- Mechanisms of Immunothrombosis by SARS-CoV-2.Biomolecules · 2021Review
- Autoinflammatory Diseases and Cytokine Storms-Imbalances of Innate and Adaptative Immunity.International journal of molecular sciences · 2021Review
- Effect of Tocilizumab in Reducing the Mortality Rate in COVID-19 Patients: A Systematic Review with Meta-Analysis.Journal of personalized medicine · 2021Article
- Tocilizumab in COVID-19: some clarity amid controversy.Lancet (London, England) · 2021Article
- Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study.Frontiers in immunologyArticle
Corrections and comments
- Commented on by
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
33356049What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.